Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives

BioDrugs

Volumn 26, Issue 4, 2012, Pages 209-215

  Zhang, Chun ^a   Yang, Xiao Lan ^a   Yuan, Yong Hua ^a   Pu, Jun ^a   Liao, Fei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Genetic engineering; Pharmacokinetics; Polyethylene glycols; Polymers; Recombinant proteins

Indexed keywords

ALPHA2 INTERFERON; AMINO ACID; ARGININE; CARBOXYLESTERASE; CYSTEINE; GLUTAMINE; LYSINE; MACROGOL DERIVATIVE; MALEIMIDE; PROTEIN; SERINE; THREONINE;

ACYLATION; ALKYLATION; AMINO ACID SEQUENCE; CHEMICAL MODIFICATION; HUMAN; IMMUNOGENICITY; MUTAGENESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; REACTION OPTIMIZATION; REVIEW;

AMINO ACIDS; BINDING SITES; DRUG CARRIERS; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; PROTEINS; SULFHYDRYL COMPOUNDS;

EID: 84863426704     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11633350-000000000-00000     Document Type: Review

References (60)

1. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003 Mar; 2 (3): 214-221
2. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977 Jun; 252 (11): 3582-6
3. Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase. Nat Rev Drug Discov 2011 Jan; 10 (1): 17-8
4. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005 Nov; 10 (21): 1451-8
5. Wada H, Imamura I, Sako M, et al. Antitumor enzyme: Polyethylene glycolmodified asparaginase. Ann N Y Acad Sci 1990 Dec; 613: 95-108
6. Payne RW, Murphy BM, Manning MC. Product development issues for PEGylated proteins. Pharm Dev Technol 2011 Oct; 16 (5): 423-440
7. Harris JM. Polyethylene glycol chemistry: Biotechnical and biomedical applications. New York: Plenum Press, 1992
8. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002 Jun; 54 (4): 459-476
9. Veronese FM, Mero A. The impact of pegylation on biological therapies. Biodrugs 2008 Sep; 22 (5): 315-329
10. Lundblad RL, Noyes CM, editors. Chemical reagents for protein modification. Boca Raton, Florida: CRC Press, 1984
11. Grace MJ, Lee S, Bradshaw S, et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-Alpha antiviral and antiproliferative activities through the JAK/STATsignaling pathway. J BiolChem2005Feb; 280 (8): 6327-6336
12. Yu PZ, Zheng C, Chen J, et al. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. Bioorg Med Chem 2007 Oct; 15 (16): 5396-5405
13. Zhang C, Yang XL, Feng J, et al. Effects of modification of amino groups with poly(ethylene glycol) on a recombinant uricase from Bacillus fastidiosus. Biosci Biotechnol Biochem 2010 Jun; 74 (6): 1298-1301
14. Veronese FM, Monfardini C, Caliceti P, et al. Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol). J Control Release 1996 Jul; 40 (3): 199-209
15. Federico R, Cona A, Caliceti P, et al. Histaminase PEGylation: Preparation and characterization of a new bioconjugate for therapeutic application. J Control Release 2006 Oct; 115 (2): 168-174
16. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002 Jun; 54 (4): 487-504
17. Besheer A, Hertel TC, Kressler J, et al. Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility. J Pharm Sci 2009 Nov; 98 (11): 4420-8
18. Fontana A, Spolaore B, Mero A, et al. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 2008 Jan; 60 (1): 13-28
19. Mero A, Schiavon M, Veronese FM, et al. A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone. J Control Release 2011 Aug; 154 (1): 27-34
20. Maullu C, Raimondo D, Caboi F, et al. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor. FEBS J 2009 Nov; 276 (22): 6741-6750
21. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006 Jan; 8 (1): R12
22. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-Asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007 Jul; 110 (1): 103-111
23. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008 Jan; 60 (1): 59-68
24. Yang XL, Yuan YH, Zhan CG, et al. Uricases as therapeutic agents to treat refractory gout: Current states and future directions. Drug Dev Res 2012 Mar; 73 (2): 66-72
25. Armstrong JK, Veronese FM. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, editor. Pegylated protein drugs: Basic science and clinical applications. Basel: Springer, 2009: 147-168
26. Ichihara M, Shimizu T, Imoto A, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011 Dec; 3: 1-11
27. Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006 May; 112 (1): 15-25
28. Wang XY, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007 Jun; 119 (2): 236-244
29. Su YC, Chen BM, Chuang KH, et al. Sensitive quantification of PEGylated compounds by second generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug Chem 2010 Jul; 21 (7): 1264-1270
30. Liu Y, Reidler H, Pan J, et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J Pharmacol Toxicol Methods 2011 Nov-Dec; 64 (3): 238-245
31. Schumacher FF, Nobles M, Ryan CP, et al. In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug Chem 2011 Jan; 22 (2): 132-6
32. Shaunak S, Godwin A, Choi JW, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2006 Jun; 2 (6): 312-3
33. Brocchini S, Godwin A, Balan S, et al. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev 2008 Jan; 60 (1): 3-12
34. Lee H, Jang IH, Ryu SH, et al. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res 2003 May; 20 (5): 818-825
35. Hu J, Sebald W. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH. Int J Pharm 2011 Jul; 413 (1-2): 140-6
36. Rosendahl MS, Doherty DH, Smith DJ, et al. A long-Acting, highly potent interferon alpha-2 conjugate created using site-specific pegylation. Bioconjug Chem 2005 Jan; 16 (1): 200-7
37. Gao M, Tian H, Ma C, et al. Expression, purification, and C-terminal sitespecific PEGylation of cysteine-mutated glucagon-like peptide-1. Appl Biochem Biotechnol 2010 Sep; 162 (1): 155-165
38. Thom J, Anderson D, McGregor J, et al. Recombinant protein hydrazides: Application to site-specific protein PEGylation. Bioconjug Chem 2011 May; 22 (6): 1017-1020
39. Wang Q, Parrish AR, Wang L. Expanding the genetic code for biological studies. Chem Biol 2009 Mar; 16 (3): 323-336
40. Neumann H, Wang K, Davis L, et al. Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome. Nature 2010 Mar; 464 (7287): 441-444
41. Voloshchuk N, Montclare JK. Incorporation of unnatural amino acids for synthetic biology. Mol Biosyst 2010 Jan; 6 (1): 65-80
42. Fang Z, Liu Y, Liu J, et al. Designing and engineering of a site-specific incorporation of a keto group in uricase. Chem Biol Drug Des 2011 Sep; 78 (3): 353-360
43. Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: Validity of computational tools. BioDrugs 2010 Feb; 24 (1): 1-8
44. Terziyska N, Grumbt B, Kozany C, et al. Structural and functional roles of the conserved cysteine residues of the redox-regulated import receptor Mia40 in the intermembrane space of mitochondria. J Biol Chem 2009 Jan; 284 (3): 1353-1363
45. Wu X, Li X, Zeng Y, et al. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expr Purif 2006 Jul; 48 (1): 24-7
46. Yoshioka Y, Watanabe H, Morishige T, et al. Creation of lysine-deficient mutant lymphotoxin-A with receptor selectivity by using a phage display system. Biomaterials 2010 Mar; 31 (7): 1935-1943
47. Narimatsu S, Yoshioka Y, Watanabe H, et al. Lysine-deficient lymphotoxinalpha mutant for site-specific PEGylation. Cytokine 2011 Nov; 56 (2): 489-493
48. MorishigeT,YoshiokaY, Inakura H, et al.Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor. Biochem Biophys Res Commun 2010 Mar; 393 (4): 888-893
49. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-Alpha with full bioactivity. Nat Biotech 2003 May; 21 (5): 546-552
50. Basu A, Yang K, Wang ML, et al. Structure-function engineering of interferonbeta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006 May; 17 (3): 618-30
51. Yoshioka Y, Tsunoda S, Tsutsumi Y. Development of a novel DDS for sitespecific PEGylated proteins. Chem Cent J 2011 May; 5: 25
52. Yoshioka Y, Tsutsumi Y, Ikemizu S, et al. Optimal site-specific PEGylation of mutant TNF-Alpha improves its antitumor potency. Biochem Biophys Res Commun 2004 Mar; 315 (4): 808-814
53. Keefe AJ, Jiang S. Poly(zwitterionic) protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat Chem 2011 Dec; 4 (1): 59-63
54. Schiavon O, Caliceti P, Ferruti P, et al. Therapeutic proteins: A comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-Acryloylmorpholine). Farmaco 2000 Apr; 55 (4): 264-269
55. Schiavon O, Pasut G, Moro S, et al. PEG-Ara-C conjugates for controlled release. Eur J Med Chem 2004 Feb; 39 (2): 123-133
56. Nojima Y, Suzuki Y, Yoshida K, et al. Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol) has an improved circulating half-life. Pharm Res 2009 Sep; 26 (9): 2125-2132
57. Li X, Lei J, Su Z, et al. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Proc Biochem 2007 Sep; 42 (12): 1625-1631
58. Bersani C, Berna M, Pasut G, et al. PEG-metronidazole conjugates: Synthesis, in vitro and in vivo properties. Farmaco 2005 Sep; 60 (9): 783-8
59. Monfardini C, Schiavon O, Caliceti P, et al. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjug Chem 1995 Jan-Feb; 6 (1): 62-9
60. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Deliv Rev 2009 Nov; 61 (13): 1177-1188